Plant Name: Schisandra chinensis
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| LTB4R; HTR2C; ADORA3; ADRA2C; ADRA2A; ADRA2B; ADRB3; DRD4; | |
| TSHR; NPSR1; TACR2; CXCR1; NMUR2; | |
| RECQL; PLA2G1B; TDP1; ALPI; FAAH; PIK3R1; GLO1; MPO; AKR1B1; HSD17B2; HSD17B10; ALOX15; HSD11B1; ALDH1A1; ALOX12; AKR1B10; NOX4; PYGL; POLB; | |
| PTPN1; | |
| ACHE; GAA; | |
| TRPV1; | |
| NEK6; PKN1; AKT1; MET; CAMK2B; CSNK2A1; DAPK1; NEK2; FLT3; SRC; IGF1R; PTK2; AURKB; ATR; GSK3B; CDK1; MAPK1; PIM1; NUAK1; ALK; AXL; KDR; | |
| CA5B; CA5A; CA3; CA14; CA7; CA1; CA12; CA9; CA4; CA6; CA2; | |
| NR0B1; | |
| ESR1; ESR2; | |
| NR3C1; | |
| KDM4E; | |
| MAOA; ALOX5; XDH; | |
| MMP13; MMP3; MMP2; MMP9; | |
| BACE1; | |
| STAT6; HIF1A; NFKB1; TP53; | |
| ABCC1; ABCB1; ABCG2; | |
| SLC6A2; SLC6A4; SLC6A3; | |
| LMNA; MAPT; GMNN; THPO; RAB9A; NPC1; PAX8; TTR; | |
| L3MBTL1; SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| ATP-binding cassette | ABCB1 | P-glycoprotein 1 | P08183 | CHEMBL4302 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
| Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 0 group B | NR0B1 | Nuclear receptor subfamily 0 group B member 1 | P51843 | CHEMBL1795094 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group C | NR3C1 | Glucocorticoid receptor | P04150 | CHEMBL2034 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Peptide receptor (family A GPCR) | TACR2 | Neurokinin 2 receptor | P21452 | CHEMBL2327 |
| Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
| Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | ATR | Serine-protein kinase ATR | Q13535 | CHEMBL5024 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
| Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
| Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| SLC superfamily of solute carriers | SLC6A2 | Norepinephrine transporter | P23975 | CHEMBL222 |
| SLC superfamily of solute carriers | SLC6A4 | Serotonin transporter | P31645 | CHEMBL228 |
| SLC superfamily of solute carriers | SLC6A3 | Dopamine transporter | Q01959 | CHEMBL238 |
| Small molecule receptor (family A GPCR) | LTB4R | Leukotriene B4 receptor 1 | Q15722 | CHEMBL3911 |
| Small molecule receptor (family A GPCR) | HTR2C | Serotonin 2c (5-HT2c) receptor | P28335 | CHEMBL225 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
| Small molecule receptor (family A GPCR) | ADRB3 | Beta-3 adrenergic receptor | P13945 | CHEMBL246 |
| Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transient receptor potential channel | TRPV1 | Vanilloid receptor | Q8NER1 | CHEMBL4794 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | GMNN | Geminin | O75496 | CHEMBL1293278 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | PAX8 | Paired box protein Pax-8 | Q06710 | CHEMBL2362980 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.977E-12 | 2.738E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, NOX4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 6.840E-12 | 4.255E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.489E-10 | 5.404E-08 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, XDH |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.085E-10 | 6.984E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, MPO, NOX4, SRC |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.214E-10 | 7.196E-08 | ALPI, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, GLO1, L3MBTL1, MMP13, MMP2, MMP3, MMP9, NR3C1, PTPN1, RXRA, TP53 |
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 3.308E-10 | 1.015E-07 | ADRA2A, ADRA2B, ADRA2C, ADRB3, DRD4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.071E-09 | 2.650E-07 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.678E-09 | 3.846E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.092E-09 | 6.293E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4 |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 3.567E-09 | 7.191E-07 | ABCB1, ABCC1, ABCG2, AKT1, ALK, ATR, AURKB, AXL, CAMK2B, CDK1, CSNK2A1, DAPK1, FLT3, GSK3B, IGF1R, KDR, MAPK1, MET, NEK2, NEK6, NUAK1, PIM1, PKN1, PTK2, PYGL, RECQL, SRC, TP53, TRPV1 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 4.593E-09 | 8.696E-07 | CYP1A2, CYP2C19, CYP2C8, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.592E-08 | 2.587E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 4.211E-08 | 5.994E-06 | AKT1, ATR, AURKB, CAMK2B, CDK1, GSK3B, MAPK1, NEK6, PKN1, SRC |
| MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 5.561E-08 | 7.475E-06 | AKT1, ALK, ATR, AURKB, CAMK2B, CDK1, CSNK2A1, DAPK1, GSK3B, MAPK1, NEK2, NEK6, NUAK1, PIM1, PKN1 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.031E-07 | 1.283E-05 | ADRA2A, ATR, AURKB, CA2, CA7, HIF1A, HTR2C, KDR, MAPK1, NEK2, NPC1, NPSR1, PLA2G1B, SRC, TRPV1 |
| MF | Unclassified; | GO:0004872; receptor activity | 1.783E-07 | 2.054E-05 | ADORA3, ADRA2A, ADRA2B, ADRA2C, ADRB3, ALK, AXL, CXCR1, DRD4, ESR1, ESR2, FLT3, HTR2C, IGF1R, KDR, LTB4R, MET, NMUR2, NPC1, NPSR1, NR0B1, NR3C1, PAX8, RXRA, TACR2, TRPV1, TSHR |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 1.867E-07 | 2.129E-05 | ADRB3, HIF1A, MMP13, MMP2, MMP3, MMP9, PLA2G1B, TRPV1 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 1.898E-07 | 2.141E-05 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0005215; transporter activity | GO:0005330; dopamine:sodium symporter activity | 1.898E-07 | 2.141E-05 | SLC6A2, SLC6A3, SLC6A4 |
| BP | GO:0009987; cellular process | GO:0030168; platelet activation | 2.489E-07 | 2.723E-05 | ADRA2A, ADRA2B, ADRA2C, AKT1, AXL, MAPK1, PIK3R1, SRC |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 3.432E-07 | 3.628E-05 | AKT1, CAMK2B, CDK1, CSNK2A1, GSK3B, MAPK1, PKN1 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 5.115E-07 | 5.109E-05 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 5.293E-07 | 5.259E-05 | AKT1, MAPT, PTPN1, SLC6A3, TP53 |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 7.559E-07 | 7.251E-05 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 7.559E-07 | 7.251E-05 | ADRA2A, ADRA2B, ADRA2C |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 7.872E-07 | 7.486E-05 | ATR, AURKB, CA2, CA7, HIF1A, MAPK1, NEK2, NPC1, NPSR1, PLA2G1B |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 9.025E-07 | 8.434E-05 | ABCC1, ALOX12, ALOX15, ALOX5, PLA2G1B |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 1.065E-06 | 9.865E-05 | CSNK2A1, HIF1A, KDR, MAPT, NR3C1 |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 1.409E-06 | 1.279E-04 | ABCC1, ADORA3, ADRA2A, ADRA2B, ADRA2C, ADRB3, ALK, AXL, BACE1, DRD4, FLT3, HTR2C, IGF1R, KDR, LTB4R, MET, NPC1, NPSR1, SLC6A2, SLC6A3, SLC6A4, TACR2, TRPV1, TSHR |
| BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 1.458E-06 | 1.317E-04 | ADRA2A, ADRA2B, ADRA2C, AKT1, SRC |
| BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 1.843E-06 | 1.639E-04 | ADRA2B, ALK, CDK1, DRD4, MAPK1, PKN1, PLA2G1B, PTPN1 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.882E-06 | 1.639E-04 | CYP1A1, CYP2C8, CYP3A4 |
| MF | GO:0005488; binding | GO:0051380; norepinephrine binding | 1.882E-06 | 1.639E-04 | ADRA2A, ADRB3, DRD4 |
| MF | Unclassified; | GO:0099600; transmembrane receptor activity | 2.649E-06 | 2.218E-04 | ADORA3, ADRA2A, ADRA2B, ADRA2C, ADRB3, ALK, AXL, CXCR1, DRD4, FLT3, HTR2C, IGF1R, KDR, LTB4R, MET, NMUR2, NPC1, NPSR1, PAX8, TACR2, TRPV1, TSHR |
| BP | GO:0023052; signaling | GO:0051583; dopamine uptake involved in synaptic transmission | 3.748E-06 | 2.978E-04 | SLC6A2, SLC6A3, SLC6A4 |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 3.748E-06 | 2.978E-04 | CYP1A1, CYP2C8, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0071880; adenylate cyclase-activating adrenergic receptor signaling pathway | 4.831E-06 | 3.784E-04 | ADRA2A, ADRA2B, ADRA2C, ADRB3 |
| MF | GO:0005488; binding | GO:0019901; protein kinase binding | 6.403E-06 | 4.927E-04 | ADRA2A, AKT1, ESR1, GSK3B, HIF1A, MAPK1, NEK6, NR3C1, PIK3R1, PKN1, PTK2, PTPN1, SRC, TP53 |
| MF | GO:0005215; transporter activity | GO:0008559; xenobiotic transmembrane transporting ATPase activity | 6.531E-06 | 4.981E-04 | ABCB1, ABCC1, ABCG2 |
| BP | GO:0008152; metabolic process | GO:0042136; neurotransmitter biosynthetic process | 6.794E-06 | 5.137E-04 | ACHE, AKT1, CYP1B1, SLC6A3, SLC6A4 |
| CC | GO:0016020; membrane | GO:0045121; membrane raft | 8.013E-06 | 6.017E-04 | BACE1, KDR, LTB4R, MAPK1, NPC1, SLC6A2, SLC6A3, SLC6A4, SRC, STAT6 |
| MF | GO:0005488; binding | GO:0042562; hormone binding | 1.001E-05 | 7.438E-04 | ACHE, ALDH1A1, IGF1R, NR3C1, PIK3R1, TTR |
| BP | GO:0009987; cellular process | GO:0010700; negative regulation of norepinephrine secretion | 1.040E-05 | 7.681E-04 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0032502; developmental process | GO:0051094; positive regulation of developmental process | 1.087E-05 | 7.967E-04 | ADRA2B, ADRA2C, AKT1, ALOX12, AXL, CA2, CAMK2B, CDK1, CYP1B1, HIF1A, HTR2C, KDR, LMNA, MAPT, NFKB1, PAX8, PIM1, SLC6A3, SRC, STAT6, THPO |
| BP | GO:0009987; cellular process | GO:0010638; positive regulation of organelle organization | 1.313E-05 | 9.346E-04 | ALOX15, ATR, AURKB, GSK3B, HIF1A, KDR, MAPK1, MAPT, MET, MMP9, NEK2, NOX4, SRC, TP53 |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 1.392E-05 | 9.790E-04 | AKT1, MAPT, NOX4, TP53, TRPV1, XDH |
| BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 2.116E-05 | 1.422E-03 | ABCG2, CA12, CA2, CA7, DRD4, ESR1, HIF1A, HTR2C, MAPK1, NMUR2, NPSR1, PLA2G1B, TP53, TRPV1 |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 2.211E-05 | 1.472E-03 | ABCB1, CA2, CA7 |
| BP | GO:0051179; localization | GO:0042908; xenobiotic transport | 2.211E-05 | 1.472E-03 | ABCB1, ABCC1, ABCG2 |
| BP | GO:0065007; biological regulation | GO:0030003; cellular cation homeostasis | 2.496E-05 | 1.632E-03 | ABCG2, CA2, CA7, DRD4, ESR1, HIF1A, HTR2C, MAPK1, NMUR2, NPSR1, PLA2G1B, TP53, TRPV1 |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 2.752E-05 | 1.757E-03 | AKR1B1, AXL, CDK1, CYP1B1, STAT6 |
| BP | GO:0008152; metabolic process | GO:0042446; hormone biosynthetic process | 2.752E-05 | 1.757E-03 | AKR1B1, CYP19A1, CYP3A4, HSD11B1, HSD17B2 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 2.882E-05 | 1.829E-03 | CA2, CA7, HTR2C, KDR, NPSR1, PLA2G1B, SRC, TRPV1 |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 2.955E-05 | 1.870E-03 | AXL, MET, NOX4, PIK3R1, PTK2, SRC, THPO |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 2.987E-05 | 1.880E-03 | AKT1, CYP1A2, MAPK1, MMP9 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 3.332E-05 | 2.044E-03 | ALOX12, ALOX15 |
| BP | GO:0009987; cellular process | GO:0038194; thyroid-stimulating hormone signaling pathway | 3.332E-05 | 2.044E-03 | PAX8, TSHR |
| MF | GO:0060089; molecular transducer activity | GO:0004996; thyroid-stimulating hormone receptor activity | 3.332E-05 | 2.044E-03 | PAX8, TSHR |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 3.332E-05 | 2.044E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 3.332E-05 | 2.044E-03 | ALOX12, ALOX15 |
| BP | GO:0050896; response to stimulus | GO:0048585; negative regulation of response to stimulus | 3.934E-05 | 2.366E-03 | ADRA2A, ADRB3, AKT1, ALOX12, ALOX15, CYP19A1, DAPK1, ESR1, ESR2, GSK3B, HIF1A, IGF1R, LMNA, MET, MMP9, NFKB1, NR0B1, PTPN1, SLC6A3, SRC, STAT6, XDH |
| BP | GO:0008283; cell proliferation | GO:0033598; mammary gland epithelial cell proliferation | 4.019E-05 | 2.398E-03 | ESR1, MAPK1, STAT6 |
| BP | GO:0065007; biological regulation | GO:0032212; positive regulation of telomere maintenance via telomerase | 4.343E-05 | 2.549E-03 | ATR, AURKB, MAPK1, NEK2 |
| BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 5.033E-05 | 2.899E-03 | ALOX15, ESR1, GSK3B, MAPT, MET, MMP3, SRC, TP53 |
| BP | GO:0002376; immune system process | GO:0048534; hematopoietic or lymphoid organ development | 5.386E-05 | 3.062E-03 | FLT3, HIF1A, KDR, L3MBTL1, MAPK1, PKN1, POLB |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 6.152E-05 | 3.417E-03 | AXL, KDR, PIK3R1, PTK2, SRC |
| BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 6.574E-05 | 3.571E-03 | MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| BP | GO:0032502; developmental process | GO:0060065; uterus development | 6.593E-05 | 3.571E-03 | CYP19A1, ESR1, SRC |
| MF | GO:0005488; binding | GO:0070405; ammonium ion binding | 6.574E-05 | 3.571E-03 | ACHE, DRD4, HTR2C, SLC6A3, SLC6A4 |
| BP | GO:0009987; cellular process | GO:1903201; regulation of oxidative stress-induced cell death | 7.018E-05 | 3.772E-03 | AKT1, HIF1A, MET, MMP3, TP53 |
| BP | GO:0051179; localization | GO:0043270; positive regulation of ion transport | 7.465E-05 | 3.974E-03 | ABCB1, ADRA2A, AKT1, DRD4, NPSR1, PLA2G1B, SLC6A4, TACR2 |
| BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 7.502E-05 | 3.984E-03 | AKT1, ATR, AURKB, CSNK2A1, L3MBTL1, NUAK1, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:2000026; regulation of multicellular organismal development | 8.358E-05 | 4.396E-03 | ADRA2B, ADRA2C, AKT1, ALOX12, AXL, CA2, CAMK2B, CDK1, CYP1B1, ESR1, GSK3B, HIF1A, KDR, L3MBTL1, MAPT, PAX8, PIK3R1, PIM1, PTK2, RXRA, SLC6A4, SRC, STAT6, THPO, XDH |
| BP | GO:0009987; cellular process | GO:1900034; regulation of cellular response to heat | 9.030E-05 | 4.678E-03 | ATR, CAMK2B, GSK3B, MAPK1, MAPT |
| BP | GO:0008152; metabolic process | GO:0031324; negative regulation of cellular metabolic process | 9.045E-05 | 4.678E-03 | ADRA2A, AKT1, ATR, AURKB, CDK1, CSNK2A1, DAPK1, DRD4, ESR1, ESR2, GMNN, GSK3B, HIF1A, IGF1R, L3MBTL1, MAPT, MET, MMP3, MMP9, NFKB1, NPC1, NR0B1, NR3C1, PKN1, PTPN1, RXRA, SRC, STAT6, TP53, TRPV1, XDH |
| BP | GO:0008152; metabolic process | GO:0006694; steroid biosynthetic process | 9.300E-05 | 4.787E-03 | AKR1B1, CYP19A1, CYP3A4, HSD11B1, HSD17B2, NR0B1 |
| BP | GO:0051179; localization | GO:0099039; sphingolipid translocation | 9.959E-05 | 5.055E-03 | ABCB1, ABCC1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 9.959E-05 | 5.055E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 9.959E-05 | 5.055E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 9.959E-05 | 5.055E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 9.959E-05 | 5.055E-03 | ALOX12, ALOX15 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 1.006E-04 | 5.070E-03 | ALOX12, ALOX15, ALOX5 |
| BP | GO:0050896; response to stimulus | GO:0001101; response to acid chemical | 1.086E-04 | 5.434E-03 | AKR1B1, AKT1, HSD17B2, KDR, MMP2, RXRA, SLC6A4, SRC, TP53 |
| MF | GO:0060089; molecular transducer activity | GO:0008528; G-protein coupled peptide receptor activity | 1.153E-04 | 5.666E-03 | CXCR1, LTB4R, NMUR2, NPSR1, TACR2, TSHR |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 1.216E-04 | 5.842E-03 | AURKB, MAPK1, NEK2 |
| MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 1.216E-04 | 5.842E-03 | AKR1B1, AKR1B10, ALDH1A1, XDH |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 1.216E-04 | 5.842E-03 | CYP2C19, CYP2C8, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 1.216E-04 | 5.842E-03 | AURKB, CDK1, PKN1 |
| BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 1.329E-04 | 6.330E-03 | AKT1, LMNA, MMP9, TP53 |
| BP | GO:0009987; cellular process | GO:0045595; regulation of cell differentiation | 1.335E-04 | 6.346E-03 | ADRA2B, ADRA2C, AKT1, AXL, CA2, CAMK2B, CDK1, GSK3B, HIF1A, HTR2C, KDR, L3MBTL1, MAPK1, MAPT, NFKB1, NR0B1, PAX8, PIK3R1, PTK2, SLC6A4, THPO, TRPV1, XDH |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 1.436E-04 | 6.768E-03 | HIF1A, MMP13, MMP2, MMP3, MMP9 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 1.436E-04 | 6.768E-03 | CYP3A4, ESR1, ESR2, NPC1, NR3C1 |
| MF | GO:0005488; binding | GO:0031690; adrenergic receptor binding | 1.453E-04 | 6.835E-03 | ADRA2A, ADRA2C, ADRB3 |
| BP | GO:0009987; cellular process | GO:0007200; phospholipase C-activating G-protein coupled receptor signaling pathway | 1.516E-04 | 7.086E-03 | ADRA2A, ESR1, HTR2C, LTB4R, NMUR2 |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 1.576E-04 | 7.335E-03 | IGF1R, KDR, PTK2, SRC |
| BP | GO:0051179; localization | GO:0006869; lipid transport | 1.652E-04 | 7.654E-03 | ABCB1, ABCC1, ABCG2, DRD4, NMUR2, NPC1, PLA2G1B, RXRA |
| BP | GO:0065007; biological regulation | GO:0032431; activation of phospholipase A2 activity | 1.984E-04 | 9.020E-03 | NMUR2, PLA2G1B |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.984E-04 | 9.020E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 1.984E-04 | 9.020E-03 | ESR1, ESR2 |
| BP | GO:0065007; biological regulation | GO:0043281; regulation of cysteine-type endopeptidase activity involved in apoptotic process | 1.994E-04 | 9.044E-03 | AKT1, CSNK2A1, DAPK1, MAPT, MMP9, SRC, XDH |
| MF | GO:0005215; transporter activity | GO:0005328; neurotransmitter:sodium symporter activity | 2.013E-04 | 9.094E-03 | SLC6A2, SLC6A3, SLC6A4 |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 2.017E-04 | 9.094E-03 | AKR1B1, AKT1, ALOX5, ATR, AURKB, CAMK2B, CDK1, CSNK2A1, ESR1, ESR2, GMNN, GSK3B, HIF1A, L3MBTL1, LMNA, MAPK1, NEK2, NEK6, NFKB1, NR0B1, NR3C1, NUAK1, PAX8, PIM1, PKN1, POLB, RECQL, RXRA, SMN1, SMN2, SRC, STAT6, TP53 |
| MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 2.038E-04 | 9.151E-03 | ABCG2, ACHE, ADRA2A, ADRA2C, ADRB3, AKT1, CAMK2B, FLT3, MAPT, NFKB1, NR0B1, PYGL, SLC6A4, XDH |
| MF | Unclassified; | GO:0032403; protein complex binding | 2.038E-04 | 9.151E-03 | ACHE, ADRA2A, ATR, FLT3, IGF1R, KDR, MMP13, MMP9, PIK3R1, PTPN1, SLC6A3, SLC6A4, SRC, TSHR |
| BP | GO:0050896; response to stimulus | GO:0006954; inflammatory response | 2.214E-04 | 9.780E-03 | ADORA3, AKT1, ALOX15, AXL, CXCR1, LTB4R, NFKB1, NOX4, POLB, TRPV1 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.014E-22 | 4.386E-18 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 9.843E-16 | 2.679E-12 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 6.385E-15 | 1.390E-11 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.234E-21 | 2.358E-19 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 7.882E-12 | 7.527E-10 | CAMK2B; SRC; MMP2; PIK3R1; HIF1A; ESR1; MMP9; PTK2; IGF1R; KDR; AKT1; MAPK1; TP53; MET |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 7.212E-10 | 2.755E-08 | GSK3B; FLT3; DAPK1; MMP2; PIK3R1; HIF1A; MMP9; NFKB1; PTK2; IGF1R; RXRA; PAX8; AKT1; MAPK1; MET; TP53 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 7.079E-10 | 2.755E-08 | CYP2C9; CYP2C8; MAOA; ALOX5; ALOX15; HTR2C; MAPK1; ALOX12; CYP2C19; SLC6A4 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 2.014E-10 | 1.282E-08 | CYP2C9; CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 5.218E-09 | 1.504E-07 | TACR2; HTR2C; TRPV1; ADRA2C; NR3C1; ADRA2B; ADRA2A; LTB4R; TSHR; ADRB3; ADORA3; NMUR2; DRD4 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 6.673E-09 | 1.593E-07 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; ESR1; NFKB1; ESR2 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 5.513E-09 | 1.504E-07 | RXRA; PAX8; FLT3; MMP3; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 2.102E-08 | 4.015E-07 | GSK3B; RXRA; SRC; AKT1; MAPK1; PIK3R1; TP53; ESR1; HIF1A |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 5.452E-08 | 8.678E-07 | CYP2C9; CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12; CYP2C19 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 8.423E-08 | 1.238E-06 | SRC; MMP2; AKT1; MAPK1; PIK3R1; ESR1; MMP9; ESR2 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.897E-08 | 4.015E-07 | HSD11B1; CYP2C9; CYP2C8; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 4.776E-07 | 5.366E-06 | GSK3B; RXRA; KDR; AKT1; MAPK1; PIK3R1; PKN1; TP53; MET; PTK2; NFKB1; IGF1R |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 3.395E-08 | 5.895E-07 | HSD11B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 9.422E-08 | 1.285E-06 | FLT3; AKT1; MAPK1; PIK3R1; TP53; MET; HIF1A |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 6.747E-07 | 6.653E-06 | GSK3B; AKT1; MAPK1; PIK3R1; TP53; NFKB1; IGF1R |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 5.775E-07 | 6.128E-06 | CAMK2B; GSK3B; SRC; AKT1; MAPK1; PIK3R1; PTK2 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.214E-06 | 1.008E-05 | PLA2G1B; MAOA; GAA; ALOX15; AKR1B1; ALOX12; PYGL; CYP2C19; CYP3A4; CYP19A1; HSD17B10; HSD11B1; CYP2C9; CYP2C8; AKR1B10; ALOX5; HSD17B2; CYP1A2; ALDH1A1; CYP1A1; ALPI; XDH |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 3.504E-07 | 4.182E-06 | ALOX5; HSD17B2; CYP1A1; CYP1B1; CYP19A1; IGF1R |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.033E-07 | 1.315E-06 | DAPK1; SRC; MMP2; MAPK1; MMP9; TP53 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 6.966E-07 | 6.653E-06 | ALK; RXRA; AKT1; MAPK1; PIK3R1; TP53 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.668E-06 | 1.250E-05 | SRC; AKT1; MAPK1; STAT6; PIK3R1; TP53; MMP9; NFKB1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 7.751E-07 | 7.049E-06 | FLT3; PIM1; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 1.165E-06 | 1.008E-05 | SRC; KDR; AKT1; MAPK1; PIK3R1; PTK2 |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 2.050E-06 | 1.398E-05 | GSK3B; SRC; KDR; AKT1; MAPK1; PIK3R1; MET; PTK2; IGF1R |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.701E-06 | 1.250E-05 | CAMK2B; AKT1; MAPK1; PIK3R1; TP53; IGF1R |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.819E-06 | 1.287E-05 | CAMK2B; AKT1; MAPK1; PIK3R1; HIF1A; NFKB1; IGF1R |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 4.546E-06 | 2.631E-05 | ADRB3; ADORA3; AKT1; MAPK1; PIK3R1; ADRA2C; ADRA2B; ADRA2A |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.701E-06 | 1.250E-05 | CYP2C9; CYP2C8; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 2.871E-06 | 1.828E-05 | AKT1; MAPK1; PIK3R1; TP53; MET; IGF1R |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 5.053E-06 | 2.757E-05 | CAMK2B; GSK3B; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.425E-06 | 1.597E-05 | CYP2C9; CYP2C8; MAOA; CYP1A2; CYP3A4; CYP2C19 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 5.053E-06 | 2.757E-05 | ABCC1; ADORA3; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 1.044E-05 | 5.195E-05 | GSK3B; CXCR1; SRC; AKT1; MAPK1; PIK3R1; NFKB1; PTK2 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 9.954E-06 | 5.138E-05 | GSK3B; RXRA; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 3.663E-06 | 2.186E-05 | PTPN1; CSNK2A1; SRC; MAPK1; MET; IGF1R |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 3.381E-06 | 2.083E-05 | HSD11B1; CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 1.152E-05 | 5.500E-05 | GSK3B; CSNK2A1; AKT1; RAB9A; PIK3R1; TP53; NFKB1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 8.803E-06 | 4.671E-05 | RXRA; AKT1; PIK3R1; TP53; NFKB1; PTK2 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 2.217E-05 | 9.848E-05 | MMP2; PIM1; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 1.867E-05 | 8.696E-05 | CAMK2B; SRC; HTR2C; ALOX12; TRPV1; PIK3R1 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 4.203E-05 | 1.638E-04 | PLA2G1B; KDR; AKT1; MAPK1; PIK3R1; MET; NFKB1; IGF1R |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 4.490E-05 | 1.715E-04 | ABCC1; ABCB1; PIM1; CYP1B1; MAPK1; TP53; MMP9; MET; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 3.416E-05 | 1.393E-04 | PTPN1; GSK3B; AKT1; PIK3R1; PYGL; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 3.597E-05 | 1.431E-04 | MMP3; AKT1; MAPK1; PIK3R1; MMP9; NFKB1 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.430E-04 | 4.709E-04 | GSK3B; CSNK2A1; CDK1; AKT1; PIK3R1; TP53; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.376E-04 | 4.610E-04 | LMNA; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.566E-04 | 5.070E-04 | POLB; SRC; CDK1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.061E-05 | 5.195E-05 | GSK3B; AKT1; MAPK1; PIK3R1; TP53 |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 8.766E-05 | 3.044E-04 | CAMK2B; GSK3B; MAOA; AKT1; SLC6A3; DRD4 |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 1.870E-04 | 5.856E-04 | SRC; KDR; AKT1; MAPK1; PIK3R1; MET; IGF1R |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 1.323E-04 | 4.511E-04 | PTPN1; GSK3B; AKT1; MAPK1; PIK3R1; PYGL |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 3.427E-05 | 1.393E-04 | AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 2.526E-05 | 1.097E-04 | GSK3B; AKT1; MAPK1; PIK3R1; TP53 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 3.427E-05 | 1.393E-04 | AKT1; MAPK1; PIK3R1; MET; HIF1A |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 5.584E-05 | 2.012E-04 | AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 5.584E-05 | 2.012E-04 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 2.260E-04 | 6.961E-04 | CDK1; AKT1; MAPK1; PIK3R1; IGF1R |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.859E-04 | 5.856E-04 | AKT1; PIK3R1; TP53; NFKB1; IGF1R |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 6.282E-04 | 1.690E-03 | POLB; GSK3B; AKT1; PIK3R1; TP53; NFKB1; ATR |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 4.026E-04 | 1.148E-03 | CAMK2B; ACHE; AKT1; MAPK1; PIK3R1 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 2.980E-04 | 8.892E-04 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 4.883E-05 | 1.829E-04 | ABCB1; RXRA; CA2; CYP3A4; ABCG2 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 8.983E-04 | 2.383E-03 | CAMK2B; AKT1; MAPK1; PIK3R1; NFKB1; TSHR |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 5.328E-04 | 1.497E-03 | ALOX5; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 1.611E-03 | 4.048E-03 | GSK3B; RXRA; AKT1; PIK3R1; NFKB1 |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 1.227E-03 | 3.168E-03 | GSK3B; AKT1; MAPK1; PIK3R1; IGF1R |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 1.965E-03 | 4.750E-03 | THPO; PIM1; AKT1; STAT6; PIK3R1 |
| hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 3.395E-03 | 7.453E-03 | ADRB3; CXCR1; SRC; KDR; MET; IGF1R |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 2.565E-03 | 6.049E-03 | BACE1; GSK3B; MAPK1; MAPT; HSD17B10 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 3.058E-03 | 6.872E-03 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 3.289E-03 | 7.305E-03 | CAMK2B; SRC; AKT1; MAPK1; NFKB1 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 2.507E-03 | 5.986E-03 | AKT1; MAPK1; PIK3R1; HIF1A |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 1.713E-03 | 4.249E-03 | CAMK2B; SRC; MMP2; MAPK1 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 2.986E-03 | 6.790E-03 | AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 4.932E-03 | 1.058E-02 | SRC; AKT1; MAPK1; PIK3R1 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 2.788E-03 | 6.415E-03 | AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 5.076E-03 | 1.077E-02 | CAMK2B; CDK1; MAPK1; IGF1R |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 1.514E-03 | 3.855E-03 | SRC; CDK1; HTR2C; MAPK1 |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 4.383E-03 | 9.513E-03 | MMP2; PIK3R1; MMP9; PTK2 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 5.223E-03 | 1.096E-02 | GSK3B; CDK1; TP53; ATR |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 6.503E-03 | 1.294E-02 | AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 5.681E-03 | 1.167E-02 | GSK3B; MAPK1; MET; PTK2 |
| hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 1.676E-02 | 2.909E-02 | CXCR1; THPO; FLT3; KDR; MET |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.442E-02 | 2.550E-02 | AKT1; MAPK1; MAPT; TP53; NFKB1 |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 6.676E-03 | 1.301E-02 | AKT1; MAPK1; PIK3R1; IGF1R |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 9.665E-04 | 2.529E-03 | SRC; PIK3R1; MET; PTK2 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 8.374E-03 | 1.568E-02 | CAMK2B; GSK3B; CSNK2A1; TP53 |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 1.205E-02 | 2.191E-02 | CAMK2B; SRC; MAPK1; PIK3R1 |
| hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 9.650E-03 | 1.772E-02 | CAMK2B; AKT1; MAPK1; PIK3R1 |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 8.786E-03 | 1.629E-02 | CXCR1; AKT1; MAPK1; PIK3R1 |
| hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 1.858E-02 | 3.127E-02 | CAMK2B; ADRB3; TACR2; HTR2C |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 2.032E-02 | 3.317E-02 | CSNK2A1; CDK1; TP53; NFKB1 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 2.735E-04 | 8.292E-04 | ADRB3; AKT1; PIK3R1; TSHR |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 3.569E-04 | 1.033E-03 | AKT1; MAPK1; PIK3R1; HIF1A |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 5.760E-04 | 1.594E-03 | CXCR1; SRC; MET; NFKB1 |
| hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 1.867E-02 | 3.127E-02 | CAMK2B; GSK3B; MAPK1 |
| hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 1.541E-02 | 2.700E-02 | AKT1; MAPK1; PIK3R1 |
| hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 1.916E-02 | 3.182E-02 | CAMK2B; AKT1; PYGL |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 1.867E-02 | 3.127E-02 | PIK3R1; NFKB1; PTK2 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 1.250E-02 | 2.252E-02 | MAPK1; PKN1; NFKB1 |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 6.579E-03 | 1.295E-02 | AKT1; MAPK1; PIK3R1 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 1.987E-05 | 9.034E-05 | RXRA; PAX8; MAPK1; TP53 |
| hsa05031 | Amphetamine addiction_Homo sapiens_hsa05031 | 6.314E-03 | 1.269E-02 | CAMK2B; MAOA; SLC6A3 |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 5.558E-03 | 1.154E-02 | AKT1; PIK3R1; IGF1R |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 7.128E-03 | 1.361E-02 | RXRA; AKT1; NFKB1 |
| hsa04115 | p53 signaling pathway_Homo sapiens_hsa04115 | 6.850E-03 | 1.322E-02 | CDK1; TP53; ATR |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 5.804E-03 | 1.179E-02 | SRC; MAPK1; NFKB1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 7.290E-05 | 2.579E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 2.612E-03 | 6.083E-03 | MAOA; NFKB1; SLC6A3 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 2.966E-02 | 4.720E-02 | MAPK1; PIK3R1 |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 1.916E-03 | 4.691E-03 | ABCC1; ABCB1; ABCG2 |
| hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 2.631E-02 | 4.259E-02 | AKT1; PIK3R1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 2.741E-02 | 4.399E-02 | CYP3A4; XDH |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 2.013E-02 | 3.314E-02 | MAPK1; PIK3R1 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 6.217E-04 | 1.690E-03 | AKR1B10; GAA; AKR1B1 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 1.382E-02 | 2.466E-02 | AKR1B10; AKR1B1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 1.730E-02 | 2.976E-02 | AKR1B10; AKR1B1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 7.282E-03 | 1.377E-02 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 3.074E-04 | 9.033E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Xerophthalmia | E50.6-E50.7 | NR3C1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pathological pain | R52, G89 | TRPV1 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5; NR3C1; NR3C1; NR3C1; TACR2; ADRB3 |
| NA: NA | Chronic low back pain | NA | SLC6A4 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | ATR |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; ESR1; ESR1 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| A00-B99: Certain infectious and parasitic diseases | Postherpetic neuralgia | B02.2, G44.847, G53.0 | TRPV1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; FAAH |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Musculoskeletal pain | R52, G89 | TRPV1 |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; NR3C1 |
| NA: NA | Depressive disorders | NA | SLC6A4 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; HTR2C; NR3C1; ADRA2C; SLC6A2; SLC6A2; SLC6A2; SLC6A2; SLC6A4; SLC6A4; SLC6A4; TACR2; TACR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; HSD11B1; HSD11B1; PTPN1; HTR2C; GSK3B; ADRB3 |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | SLC6A2 |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; ESR1 |
| C00-D49: Neoplasms | Neuroendocrine cancer | C7A | SLC6A2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1 |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; TP53 |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3; ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | SLC6A4 |
| NA: NA | Sleep initiation and maintenance disorders | NA | HTR2C |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | SLC6A2 |
| A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TP53; KDR; KDR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | TRPV1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cushing's disease | E24.0 | NR3C1 |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | LTB4R |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | NR3C1 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC; ESR1 |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC; ADORA3 |
| I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome with diarrhoea | A09, J45, K58, K59.1 | TACR2 |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | TACR2; ADRB3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR2C |
| K00-K95: Diseases of the digestive system | Gastroesophageal reflux disease | K21 | TRPV1 |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ADRB3 |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Duchenne muscular dystrophy | G71.0 | NR3C1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | HTR2C |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cancer pain | R52, G89 | SLC6A2 |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | AKT1; MET; CSNK2A1; ABCB1; CA1; FLT3; FLT3; CA9; MMP2; ACHE; SRC; IGF1R; PTK2; ATR; GSK3B; ADORA3; HIF1A; CDK1; MAPK1; MMP9; NFKB1; NR3C1; PIM1; SLC6A4; TP53; ESR1; ESR1; KDR |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; MMP13; ALOX5; NR3C1; FAAH; SLC6A4; LTB4R |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | LTB4R |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; ALOX5; NR3C1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| NA: NA | GIST | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1; ACHE; ADORA3; ADRA2C; ADRB3 |
| C00-D49: Neoplasms | Glioma | C71 | KDR |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | TRPV1; TRPV1; ADRB3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; TRPV1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | ADRB3 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | HTR2C |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| NA: NA | Edema | NA | CA2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Eczema | L20-L30 | NR3C1 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | MMP3 |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HSD11B1; HTR2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; TRPV1; ADRA2B; SLC6A4; SLC6A4 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | HTR2C; ADRA2C; NPSR1; ESR1 |
| C00-D49: Neoplasms | Neuroblastoma | C74.1, C74.9, C75.4, C75.5, D35.0, D35.5, D35.6, D44.6, D44.7 | SLC6A2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1; ALOX5 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; KDR |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| N00-N99: Diseases of the genitourinary system | Vasomotor symptoms | N95.1 | SLC6A4 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; ABCB1; IGF1R; IGF1R; AXL; KDR |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; KDR |
| NA: NA | Non-infectious rhinitis | NA | NR3C1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HSD11B1; PTPN1; HTR2C; HTR2C; ADRA2C; SLC6A2; SLC6A4; ADRB3; ADRB3; ADRB3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depression | F32, F33 | SLC6A4 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA; HTR2C; HTR2C; SLC6A2; FAAH; SLC6A4; SLC6A4; ADRB3; ADRB3 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
| NA: NA | Esophagus sensitivity | NA | TRPV1 |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; ADORA3; KDR |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | NR3C1; ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | HTR2C; DRD4 |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; CA9; HIF1A |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | MMP13; HTR2C; ACHE; TRPV1; TRPV1; IGF1R; CDK1; ADRA2C; ADRA2A; SLC6A2; FAAH; SLC6A4; TACR2; ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; XDH |
| C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
| H60-H95: Diseases of the ear and mastoid process | Otitis externa | H60 | NR3C1 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | ABCB1; MMP2; KDR; KDR; KDR; KDR |
| NA: NA | Myalgia | NA | SLC6A4 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO; NR3C1; ESR1; ESR1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | SRC; IGF1R |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR2C; SLC6A4; DRD4 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; ACHE; SLC6A4 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; FLT3; MMP2; LTB4R; KDR |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA; HTR2C; SLC6A4 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2B; AKR1B1; PLA2G1B; MMP3; ALOX5; NR3C1; LTB4R |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5; NR3C1 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
| NA: NA | Infantile colics | NA | TACR2 |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | SLC6A4 |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | ABCB1; CYP2C9 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | TRPV1; ALOX5; NR3C1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A; SLC6A2; SLC6A2; SLC6A4 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | AKT1; MET; ABCB1; FLT3; CA9; MMP2; SRC; IGF1R; PTK2; AURKB; ATR; HIF1A; MAPK1; MMP9; TP53; KDR; KDR; KDR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Spinal cord injury | S14, S24, S34 | NR3C1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Smoking cessation | F17.2 | SLC6A4 |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | TRPV1; TACR2; TACR2; ADRB3 |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | NR3C1 |
| NA: NA | Appetite suppressant | NA | SLC6A4 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B; TRPV1; ALOX5; ALOX5; NR3C1; NR3C1; NR3C1; NR3C1; ADRA2C; TACR2; ADRB3; ADRB3; LTB4R |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ALOX5 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| K00-K95: Diseases of the digestive system | Postoperative ileus | K31.5, K56.0, K56.3, K56.7, P76.1 | TACR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | SLC6A4 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Skin allergies | T78.4 | NR3C1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2B; MAOA; HTR2C; ACHE; NR3C1; SLC6A2; FAAH; TACR2; CYP3A4 |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
| NA: NA | Anxiety disorders | NA | TACR2 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C; SLC6A2; SLC6A4; SLC6A4 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; IGF1R; MMP9; TP53; KDR |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | TTR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | SLC6A2 |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; ESR1 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| NA: NA | Primary insomnia | NA | HTR2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; ALOX5; LTB4R |
| NA: NA | Corticosteroid-responsive inflammation | NA | NR3C1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| C00-D49: Neoplasms | AML | NA | FLT3; KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; MAPT; ACHE; ACHE; ACHE; GSK3B; ADRA2C |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5; LTB4R |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B; NR3C1; ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | HSD11B1; PTPN1; PTPN1; NFKB1; NR3C1; ADRB3; ADRB3; ADRB3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; LTB4R; KDR |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| NA: NA | Menopausal staging | NA | SLC6A4 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; HTR2C; ADRA2C; ADRA2B |
| C00-D49: Neoplasms | Aggressive non-hodgkin's lymphoma | C81, C81-C86, C82-C85, C91-C95 | HTR2C |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; LTB4R; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; LTB4R |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1; ADRA2C; CA4; CA4 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | NR3C1; ADRB3 |
| C00-D49: Neoplasms | Breast cancer | C50 | FLT3; FLT3; CA9; IGF1R; CYP19A1; CDK1; ESR1; ESR1; KDR; KDR; KDR |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C; ADRB3 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ABCB1; ESR1 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; CYP19A1 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP13; MMP3; MMP2; ALOX5 |
| NA: NA | Chemotherapyinduced emesis | NA | SLC6A4 |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; CA2 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; AURKB; TP53 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; AURKB; TP53; TP53 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | TRPV1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Acute or chronic pain | R52, G89 | TRPV1; TACR2 |